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ABSTRACT 
Endometrial cancer is a common malignant gynecological tumor, but there are few biomarkers that are useful for 
early and accurate diagnosis and few treatments other than surgery. However, use of microRNAs (miRNAs) that 
induces gene downregulation in cells may permit effective and minimally invasive diagnosis and treatment. In 
endometrial cancer cells, expression levels of miRNAs including miR-185, miR-210 and miR-423 are upregulat-
ed and those of miR-let7e, miR-30c and miR-221 are downregulated compared to normal tissues, and these 
miRNAs are involved in carcinogenesis, invasion and metastasis. miRNAs with expression changes such as 
miR-181b, miR-324-3p and miR-518b may be used as prognostic biomarkers and transfection of miR-152 may 
inhibit cancer growth. However, most current studies of miRNAs are at a basic level and further work is needed 
to establish clinical applications targeting miRNAs. 
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INTRODUCTION 
microRNA (miRNA) is of interest as a 
regulatory mechanism in genomic expres-
sion. The human genome project identified 
approximately 20,000 genes in humans, but 
only 2 % of these genes are translated into 
proteins (International Human Genome Se-
quencing Consortium, 2004). A large-scale 
transcriptome analysis showed that RNAs 
are also transcribed in several noncoding re-
gions, in which gene sequences of proteins 
are not encoded. These so-called non-coding 
RNAs (ncRNAs) have complex functions in-
cluding regulation of chromatin structure, 
splicing, and protein silencing. 
miRNA is the most important class of 
ncRNAs. miRNAs are small RNA molecules 
of about 22 nucleotides that induce gene si-
lencing. About 2,000 miRNAs have been 
found in humans and these molecules are 
important for biological activities including 
development; cell differentiation, prolifera-
tion and death; and metabolism (Stefani and 
Slack, 2008; Elbashir et al., 2001). Various 
diseases are caused by breakdown of gene 
regulatory networks due to changes in miR-
NA levels, and the relationship of miRNAs 
with cancer is under investigation. 
One miRNA regulates many messenger 
RNAs (mRNAs), while cancer does not de-
velop due to a single cause, but due to 
breakdown of multiple mechanisms. There-
fore, in contrast to common drugs, miRNAs 
may be used as treatment through compre-
hensive regulation of expression of mole-
cules related to cancer. Use of miRNAs may 
also contribute to elucidation of oncogenic 
and homeostatic mechanisms. In this article, 
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we summarize the latest studies on applica-
tion of miRNAs in diagnosis and treatment 
for endometrial cancer, based on malignant 
transformation associated with abnormal 
miRNA expression. 
 
miRNA AND CANCER 
miRNA-induced RNA silencing is in-
volved in homeostatic maintenance of organ-
isms and breakdown of this mechanism 
causes disease. Cancer is among the best-
studied diseases caused by failure of miRNA 
regulation. miRNAs are implicated in cancer 
development and progression, and expres-
sion patterns of miRNAs in normal tissues 
differ from those of cancer tissues. miRNAs 
involved in cancer are classified into onco-
genic miRNAs (oncomiRs), which are up-
regulated in tumor tissues; and tumor sup-
pressor miRNAs (tumor suppressor miRs), 
which are downregulated in tumor tissues 
and inhibit cancer. OncomiRs target mRNAs 
that suppress tumor growth, whereas tumor 
suppressor miRs target mRNAs that promote 
tumor growth. Failed regulation of both 
types of miRNAs promotes oncogenesis, 
proliferation and invasion of cancer cells, 
and the epithelial-mesenchymal transition 
(EMT) (Figure 1). 
Involvement of miRNAs in human can-
cer was first shown in B cell chronic lym-
phocytic leukemia (CLL), in which expres-
sion of miR-15 or miR-16 was found to de-
crease (Calin et al., 2002). In cancers, miR-
17-92 is upregulated in lung cancer cells 
(Hayashida et al., 2005). A large-scale analy-
sis of miRNA expression in 540 patients 
with lung, breast, gastric, prostate, colon and 
pancreatic cancer showed that expression 
profiles of miRNAs in cancer tissues differ 
from those in normal tissues (Volinia et al., 
2006). miR-21 was particularly upregulated 
in all types of cancer, indicating that it is 
likely to be involved in cancer onset. Subse-
quently, miR-21 was shown to regulate tran-
scriptional repressors including NFIB (Fujita 
et al., 2008). Upregulation of miR-21 down-
regulates transcriptional repressors, resulting 
 
Figure 1: Changes in miRNA expression and 
oncogenic mechanisms. Upregulation of on-
comiRs inhibits expression of tumor-suppressor 
mRNAs, resulting in enhanced oncogenesis be-
cause tumor suppression effects are lost. In con-
trast, downregulation of tumor-suppressor miRs 
reduces inhibition of expression of oncogene 
mRNAs, and the resultant upregulated expres-
sion of these mRNAs facilitates oncogenesis. 
 
in transcriptional activation; therefore, miR-
21 is considered to be a typical oncomiR. 
miRNAs that are downregulated in can-
cer have also been found. For example, let-7, 
which was found in C. elegans and is in-
volved in cell growth, is a typical miRNA 
precursor that is downregulated in breast, 
lung and gastric cancer. let-7 targets onco-
genes including RAS and high mobility 
group AT-hook 2 (HMGA2) and has been 
shown to be a tumor suppressor miR (John-
son et al., 2005; Lee and Dutta, 2007; Yu et 
al., 2007). Some miRNAs have carcinoma-
specific differential expression. The relation-
ship of many of these miRNAs with their 
target genes is unknown, but miR-19 is nec-
essary for inhibition of apoptosis and onco-
genesis in lymphocytes (Olive et al., 2009). 
Chen et al. (2007) found that undifferentiated 
cell clusters including embryonic stem (ES) 
cells, embryoid bodies and mouse 11-day 
embryos had expression profiles of miRNAs 
that were simpler than those of mature so-
matic cells. These results suggest that the dif-
ferentiation stage may be defined by profiles 
of specific miRNAs. It is also of note that 
miRNA profiles in undifferentiated stem 
cells are similar to those of cancer cells. 
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ENDOMETRIAL CANCER AND miRNA 
Endometrial cancer is the most frequent 
among malignant female genital cancers and 
approximately 80 % of cases have a histo-
logical type of endometrioid adenocarcinoma 
(Amant et al., 2005). The oncogenic pattern 
of endometrial cancer and factors for metas-
tasis and invasion have been established and 
the expression pattern of miRNAs differs 
from that of normal endometrium (Table 1). 
Among endometrial cancers, endometrioid 
carcinoma and papillary carcinoma also have 
different miRNA expression (Chan et al., 
2011). 
In endometrial cancer, miRNAs includ-
ing miR-185, miR-106a, miR-181a, miR-
210, miR-423, miR-103, miR-107, miR-
let7c, miR-205, miR-449 and miR-429 are 
upregulated and involved in oncogenesis, in-
vasion and metastasis (Boren et al., 2008; 
Wu et al., 2009; Chung et al., 2009). miR-7 
is also upregulated in endometrial cancer, 
and invasion and cancer cell migration are 
inhibited by downregulation of miR-7 using 
an anti-miRNA antibody (Chung et al., 
2012). In endometrioid adenocarcinoma, up-
regulation of miR-27 expression is surgical 
stage-dependent. miR-27 contributes to sur-
vival of tumor cells through the resultant re-
duced expression of FOXO1, a target gene of 
miR-27 that inhibits apoptosis (Mozos et al., 
2014). 
Dai et al. (2013) found that miR-200b 
overexpression in adenocarcinoma cell lines 
inhibited expression of tissue inhibitor of 
metalloproteinase-2 (TIMP2) and increased 
the level of matrix metalloproteinase (MMP) 
2, indicating that miR-200b is involved in 
metastasis of endometrial cancer. Six miR-
NAs show specific expression patterns in ad-
enocarcinoma, including miR-34b, which is 
methylated in the promoter region in adeno-
carcinoma and is involved in proliferation 
and invasion (Hiroki et al., 2012). In con-
trast, multiple miRNAs including miR-let7e, 
miR-30c, miR-221, miR-152, miR-193, 
miR-204, miR-99b and miR-193b are down-
regulated in endometrial cancer (Boren et al., 
2008; Wu et al., 2009; Chung et al., 2009). 
These miRNAs inhibit oncogenesis, invasion 
and metastasis, and these phenomena are in-
duced by downregulation of the miRNAs. 
 
 
Table 1: Changes in expression of miRNAs in endometrial cancer 
Upregulation
(OncomiRs) Target genes References
miR-185
miR-106a
miR-181a
miR-210
miR-423
miR-103      Boren et al., 2008; Wu et al., 2009; Chung et al., 2009
miR-107
miR-let7c
miR-205
miR-449
miR-429
miR-7 Chung et al., 2012
miR-27 FOXO1 Mozos et al., 2014
miR-200b TIMP2 Dai et al., 2013
miR-34b Hiroki et al., 2012
Downregulation
(Tumor-suppressor miRs) Target genes References
miR-let7e
miR-221
miR-193     Boren et al., 2008; Wu et al., 2009; Chung et al., 2009
miR-99b
miR-193b
miR-204 FOXC1 Boren et al., 2008; Wu et al., 2009; Chung et al., 2009; Chung et al., 2012
miR-152 DNMT1, E2F3, MET, Rictor Boren et al., 2008; Wu et al., 2009; Chung et al., 2009; Tsuruta et al., 2011; Banno et al., 2012
miR-30c MTA1 Xie Y et al., 2011; Zhou H et al., 2012; Kong et al., 2014
miR-129-2 SOX4, hMLH1 Huang et al., 2011; Banno et al., 2012; Huang et al., 2014
miR-203 Huang et al., 2014
miR-106b TWIST1 Dong et al., 2014
miR-let7a Aurora-B Liu et al., 2013  
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miRNAs are also involved in DNA 
methylation during progression of endome-
trial cancer. For example, if expression of 
miR-129-2 is enhanced by epigenetic mech-
anisms including DNA demethylation and 
histone acetylation, expression of SRY-
related high-mobility group box 4 (SOX4) is 
suppressed and growth of endometrial cancer 
is inhibited. In endometrial cancer, this 
mechanism fails and SOX4 is overexpressed 
(Huang et al., 2009). miR-129-2 is involved 
in microsatellite instability and methylation 
of human mutL homolog 1 (hMLH1), a DNA 
mismatch repair (MMR) gene implicated in 
progression of type I endometrial cancer. 
hMLH1 is frequently methylated in endome-
trial cancer tissues and may induce mutation 
of cancer-associated genes including human 
mutS homolog 6 (hMSH6), type II trans-
forming growth factor-beta (TGF-βII), Bcl2-
associated X protein (BAX) and PTEN 
(Banno et al., 2012). In addition to miR-129-
2, miR-203 also regulates SOX4, and meth-
ylation of these miRNAs may lead to devel-
opment of endometrial cancer (Huang et al., 
2014). 
Expression of miR-152 is regulated by 
methylation and is downregulated in endo-
metrial cancer. miR-152 inhibits expression 
of targets including DNA methyltransferase 
(DNMT1), E2F3, met proto-oncogene 
(MET) and rapamycin-insensitive compan-
ion of mTOR (Rictor), all of which are im-
plicated in oncogenesis. Thus. treatment tar-
geting miR-152 and use of this miRNA as a 
biomarker have potential (Banno et al., 2012; 
Tsuruta et al., 2011). miR-106b inhibits EMT 
and TWIST1 (Dong et al., 2014) and metas-
tasis is promoted by downregulation of miR-
106b. let-7a inhibits Aurora-B and reduces 
the level of Aurora-B protein, with resultant 
inhibition of endometrial cancer onset (Liu et 
al., 2013). miR-204 also regulates metastasis 
and invasion of tumor cells in the endome-
trium. A target of miR-204, forkhead box C1 
(FOXC1), regulates metastasis and invasion 
in human endometrial cancer-derived 
HEC1A cells. In endometrial cancer, FOXC1 
is overexpressed due to downregulation of 
miR-204 and this promotes metastasis and 
invasion of tumor cells (Chung et al., 2012). 
miR-30c acts directly on metastasis-
associated gene-1 (MTA1). miR-30c inhibits 
cell proliferation in the endometrium via 
regulation of MTA1, and thus downregula-
tion of miR-30c may be involved in typeⅠ
andⅡendometrial cancer (Xie et al., 2011; 
Zhou et al., 2012). miR-30c is also downreg-
ulated by estradiol (E2) in estrogen receptor 
(ER)-positive Ishikawa cells and ER-
negative HEC1B cells, which indicates that 
estrogen regulates miR-30c in the endome-
trium and is involved in oncogenesis of en-
dometrial cancer (Kong et al., 2014). Lin et 
al. (2008) showed that miR-302 induces de-
methylation of overall genomic DNA, and 
consequently activates transcription factors 
including Oct4, Sox2, Nanog and Lin28. Ex-
pression of specific genes in human ES cells 
causes reprogramming in these cells, with 
somatic cells changed to pluripotent stem 
(mirPS) cells. miR-302 inhibits tumorigene-
sis in various cancers, including through di-
rect inhibition of cyclin D1 and indirect in-
hibition of CDK1 (Yan et al., 2014). 
Many important findings have been de-
scribed in this section, but it is also clear that 
an understanding of the mechanisms of 
miRNAs in endometrial cancer requires fur-
ther studies. 
 
APPLICATION OF miRNA IN ENDOME-
TRIAL CANCER AS A BIOMARKER 
Valadi et al. reported the initial finding of 
extracellular miRNAs in exosomes (Valadi et 
al., 2007). Exosomes are extracellular vesi-
cles and miRNA carriers that are released 
from cells into blood. Catabolic enzymes for 
miRNA are present in serum and it was orig-
inally thought that miRNAs could not exist 
in blood. However, miRNAs in exosomes are 
stable and are present in blood (Chim et al., 
2008; Gilad et al., 2008). Exosomes released 
from cancer cells may have a relationship 
with mechanisms including immunosuppres-
sion, drug resistance and angiogenesis. Thus, 
miRNAs in exosomes reflect cell characteris-
tics and overexpressed miRNAs in cancer 
cells are included in exosomes released from 
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these cells. Lawrie et al. (2008) first showed 
that cancer-specific miRNAs were effective 
biomarkers, and subsequently development 
of biomarkers using miRNAs has increased. 
Several miRNAs have specific expres-
sion profiles in particular carcinomas and are 
likely to be useful as biomarkers. Analysis of 
miRNAs may classify cancer more correctly 
than analysis of 20,000 mRNAs (Lu et al., 
2005). Lung cancer with downregulation of 
let-7 has a poor prognosis after surgery, indi-
cating that miRNAs may be markers for 
prognosis, as well as for early diagnosis 
(Takamizawa et al., 2004). Most patients 
with endometrial cancer are diagnosed at an 
early clinical stage. However, the 5-year sur-
vival rate of patients in whom endometrial 
cancer is detected at an advanced stage is 
low, ranging from 10 % to 29 %. Therefore, 
development of a specific marker is required 
for early detection of endometrioid adeno-
carcinoma (Bansal et al., 2009). For exam-
ple, Tan et al. (2010) found that upregulation 
of miR-155 was related to cancer stage and 
lymph node metastases in a study of miR-
155 in serum that had the goal of detection 
of differences in miRNA expression among 
endometrioid adenocarcinoma, normal en-
dometrium, and other tissue types.  
Endometriosis is one of precancerous le-
sion of endometrial cancer that is a target for 
early diagnosis. A combination of miR-199a 
and miR-542-3p can be used to diagnose en-
dometriosis with a sensitivity of 96.61 % and 
specificity of 79.66 %, and this approach 
may serve as a noninvasive marker in prac-
tice (Yu et al., 2012). Torres et al. (2012) 
found that expression of miR-99a, miR-100 
and miR-199b was upregulated in serum of 
patients with endometrioid adenocarcinoma, 
and showed that a combination of miR-99a 
and miR-199b had a higher diagnostic value 
than each miRNA alone. Analysis of miR-
NAs in serum in a genome-wide study 
showed that a combination of four serum 
miRNAs, miR-222, miR-223, miR-186 and 
miR-204, can be used to diagnose endome-
trioid adenocarcinoma with high probability. 
Use of this combination for diagnosis gave 
an area under the ROC curve of 0.927, which 
was higher than that for the currently used 
marker, CA-125 (0.673). 
TypeⅡ endometrial cancer is difficult to 
diagnose because it involves de novo onco-
genesis and has no precancerous lesion. 
However, several miRNAs including miR-
125b may be useful for diagnosis of endome-
trial cancer. Expression of miR-125b in type
Ⅱendometrial cancer cells is significantly 
upregulated compared to that in typeⅠ cells. 
Tumor protein p53 inducible nuclear protein 
1 (TP53INP1) gene, a target of miR-125b, 
may be related to malignancy of typeⅡ
endometrial cancer because cancer cells pro-
liferate when this gene is not regulated 
(Jiang et al., 2011). V-erb-b2 erythroblastic 
leukemia viral oncogene homolog 2 
(ERBB2), a second target of miR-125b, is al-
so involved in invasion of cancer cells 
(Shang et al., 2012). miR-194 may also be a 
biomarker for prognostic diagnosis of endo-
metrial cancer. miR-194 is markedly de-
creased in endometrial cancer and this de-
crease is correlated with the stage of cancer 
and is associated with prognosis (Zhai et al., 
2013). Administration of pre-miRNA 
showed that miR-194 targets the oncogene 
BMI1 and inhibits the EMT phenotype and 
EC cell invasion (Dong et al., 2011). 
KRAS mutation frequently occurs in type
Ⅱ endometrial cancer. Expression levels of 
miR-181b, miR-324–3p and miR-518b are 
downregulated in cancer with a KRAS muta-
tion (Lee et al., 2014). Thus, miR-181b, 
miR-324–3p and miR-518b may be prognos-
tic markers. miR-205 targeting PTEN is also 
associated with decreased survival. Expres-
sion profiles of miRNAs in endometrioid ad-
enocarcinoma may also be implicated in 
clinicopathologic characteristics (Torres et 
al., 2013; Tsukamoto et al., 2014), with ex-
pression of several miRNAs showing a rela-
tionship with International Federation of 
Gynaecology and Obstetrics (FIGO) staging, 
cancer grade, recurrence and lymph node 
metastasis.  
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APPLICATION OF miRNA FOR TREAT-
MENT OF ENDOMETRIAL CANCER 
miRNAs have a close relationship with 
cancer, and therefore may be useful for can-
cer treatment. Two approaches have been 
proposed as therapeutic strategies involving 
miRNAs. The first is replacement therapy 
with a particular miRNA for which down-
regulation is associated with disease onset. 
The second is replacement of molecules in-
hibiting a certain miRNA for which upregu-
lation is associated with onset. The first ap-
proach includes treatment with viral vectors 
and ribosomes. miR-16 supplemented in 
bone metastasis model mice with prostate 
cancer reduced proliferation of local tumors 
and bone metastasis was significantly inhib-
ited without adverse reactions. These results 
suggest that supplementation of downregu-
lated miRNA can have a therapeutic effect 
(Takeshita et al., 2010). Similarly, admin-
istration of miR-143 inhibited metastasis in 
pulmonary metastasis model mice with oste-
osarcoma (Osaki et al., 2011). The second 
approach includes inhibition of a target 
miRNA using locked nucleic acid (LNA). 
Using this approach, activities of miR-122 in 
primates with hepatitis C were inhibited 
without serious adverse reactions and HCV 
proliferation was also inhibited (Randall et 
al., 2007; Lanford et al., 2010). 
Studies of miRNAs have revealed de-
tailed mechanisms of drugs. Such drugs in-
clude bortezomib, an inhibitor of ubiquitin-
dependent proteolysis that kills tumor cells 
in vitro and in animal models. This drug 
blocks proteasome activity, arrests cells in 
G2/M phase, induces apoptosis, and inhibits 
development of endometrial cancer. The ac-
tion of miR-17-5p on p21 increased the effi-
cacy of bortezomib (Shen et al., 2013). 
Drug sensitivity of cancer can also be in-
fluenced using miRNAs. In endometrial can-
cer, expression of miR-34c, which regulates 
metastasis, cell death and invasion, is mark-
edly downregulated, and a combination of a 
miR-34c mimic with cisplatin improved the 
drug efficacy in cell lines (Jiang et al., 2013). 
Expression of miR-200b, miR-200c and 
miR-429, which inhibit transcription factor 
AP-2α, is upregulated in endometrial cancer 
and the rate of expression is positively corre-
lated with resistance to cisplatin. However, 
SNP (rs1045385A>C) decreases the effect 
on AP-2α, and sensitivity to cisplatin is in-
creased (Wu et al., 2011). These studies sug-
gest that a comprehensive investigation of 
which miRNA causes resistance or increases 
sensitivity to a particular drug will improve 
selection of drug treatment. 
miRNAs themselves can be used for can-
cer treatment as a means of increasing ex-
pression of tumor suppressor genes and in-
hibiting oncogenes. Administration of a tu-
mor suppressor miR, miR-152, in vitro and 
in vivo gave significant tumor suppression 
(Tsuruta et al., 2011). However, no miRNA 
is currently used in clinical practice, in part 
because application of miRNAs depends on 
effective and cancer cell-specific transport. 
miRNAs exist stably in various tissues and 
structures, and therefore should be relatively 
easy to transport into cells via blood vessels 
and other structures (Mitchell et al., 2008). 
Transport methods for short interfering RNA 
(siRNA) should also be applicable to miRNA 
(Gondi and Rao, 2009; Broderick and Zamo-
re, 2011) due to the structural similarity of 
miRNA and siRNA. Nanoparticles contrib-
ute to the stability of miRNAs (Kong et al., 
2012) and liposome-polycation-hyaluronic 
acid (LPH) modified with a single-chain an-
tibody fragment (scFv) has been used for 
transport of miRNAs and siRNAs into can-
cer cells, with resultant downregulation of 
target genes (c-Myc, MDM2 and VEGF). In-
travenous injection of nanoparticles modified 
with a humanized monoclonal antibody GC4 
and miR-34a and two siRNAs also resulted 
in significant accumulation in cancer cells 
and inhibition of expression of target genes 
(Chen et al., 2010). 
These results suggest that miRNAs can 
be transported specifically into cancer cells 
using nanoparticles modified with antibodies 
to cancer cell surface markers, and that a 
combination of siRNAs and miRNAs can in-
crease the efficiency of gene regulation. Ef-
fects of miRNAs are relatively mild in com-
parison with molecular targeted drugs, but 
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miRNAs inhibit expression of multiple target 
molecules and cause fewer adverse reactions 
in normal cells. 
 
CONCLUSION 
It is only 20 years since miRNAs were 
discovered, but many mechanisms have now 
been elucidated. Cancer cells include miR-
NAs with cancer-specific upregulation and 
downregulation, and these miRNAs are in-
volved in oncogenesis, invasion and metasta-
sis. miRNAs with expression patterns that 
differ from those in normal tissues, such as 
miR-125b, may be useful in treatment and as 
biomarkers for endometrial cancer. These 
miRNAs are currently being studied at an 
investigational level prior to development of 
clinical applications. 
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